What Is an IL-6 Test and What Do the Results Mean?

An IL-6 test measures the concentration of interleukin-6, a signaling protein (cytokine) that the body releases rapidly in response to infection, tissue injury, and inflammation. In clinical practice, the test is most often ordered to help detect sepsis, monitor inflammatory conditions like rheumatoid arthritis, and track dangerous immune reactions during treatments such as CAR T-cell therapy. Because IL-6 rises within hours of an inflammatory trigger and falls quickly once the trigger resolves, it fills a diagnostic gap that slower markers like C-reactive protein cannot.

What IL-6 Does and Why Measuring It Matters

IL-6 is one of the first cytokines the immune system produces when it senses trouble. Infections, surgical trauma, burns, and autoimmune flares all provoke a burst of IL-6, which then travels to the liver and drives the production of acute-phase proteins, including C-reactive protein (CRP), fibrinogen, and serum amyloid A.¹ In short, IL-6 is the upstream alarm that triggers much of the downstream inflammatory cascade you can detect in routine blood work. CRP, for example, does not start climbing until the liver receives the IL-6 signal, which is why IL-6 levels spike hours before CRP does.

Under normal circumstances IL-6 production is tightly controlled: it rises fast, does its job, and shuts off. When that off-switch fails and IL-6 keeps being produced continuously, the result is chronic inflammation, which plays a role in autoimmune diseases, certain cancers, and metabolic syndrome.² This dual personality is what makes the IL-6 test clinically useful in such varied contexts: a single measurement can flag an acute crisis, and serial measurements can reveal whether a chronic condition is active or quieting down.

When Doctors Order the Test

The IL-6 test is not part of routine blood panels. It is typically ordered in specific clinical scenarios where rapid, early detection of inflammation changes what happens next. The most common reasons include:

Suspected sepsis: IL-6 rises within two to four hours of a systemic infection, well before CRP or procalcitonin show meaningful changes. In intensive care, that early window can determine whether antibiotics start immediately or are delayed.
Neonatal sepsis: Newborns, especially premature infants, have limited ways to signal infection. IL-6 has become one of the preferred early biomarkers in neonatal intensive care units.
Cytokine release syndrome (CRS): Patients receiving CAR T-cell therapy for blood cancers can develop a life-threatening immune overreaction. Tracking IL-6 levels in real time helps predict which patients are heading toward severe CRS before clinical symptoms escalate.
Autoimmune and inflammatory diseases: In conditions like rheumatoid arthritis, giant cell arteritis, and Castleman disease, IL-6 levels help gauge disease activity and guide treatment decisions.
Periprosthetic joint infection: After hip or knee replacement, IL-6 measured in blood or joint fluid can help distinguish infection from mechanical loosening.

IL-6 in Sepsis Detection

Sepsis remains one of the most time-sensitive diagnoses in medicine, and IL-6 is one of the biomarkers clinicians lean on to catch it early. Its rise in the blood during the opening hours of infection, often before cultures return positive, reflects its utility as an early warning signal.³

How accurate is the test? The numbers vary depending on the study population and the comparison group. One meta-analysis found a pooled sensitivity of about 80% and specificity of about 85% for distinguishing sepsis from non-sepsis, with an area under the curve of 0.87.⁴ A more recent Cochrane review, using stricter methodology, found somewhat lower performance: around 66% sensitivity at 74% specificity.⁵ That gap matters and reflects the broader reality that no single biomarker diagnoses sepsis on its own. IL-6 works best as one piece of a puzzle that includes clinical signs, other lab markers, and imaging.

Beyond simply detecting sepsis, serial IL-6 measurements can help predict who will die from it. A prediction model combining day-one and day-three IL-6 values with procalcitonin and lactate trends achieved an area under the curve near 0.85 for forecasting 28-day mortality.⁶ In practical terms, a falling IL-6 level over the first few days of treatment is reassuring, while a level that stays high or climbs further signals that something is going wrong.

Neonatal Sepsis and IL-6

Newborns present a unique diagnostic challenge. They can deteriorate rapidly, their symptoms are nonspecific, and blood cultures take time. IL-6 has carved out a particularly important role in neonatal medicine because it appears in the blood earlier than CRP, which can take 12 to 24 hours to rise after an infection begins.

For late-onset neonatal sepsis, a recent meta-analysis reported pooled sensitivity of about 85% and specificity of about 84%, with a diagnostic odds ratio of 31.4 and an area under the curve of 0.91.⁷ Those numbers translate to a test that is good enough to meaningfully influence whether a clinician starts antibiotics immediately or waits for further workup.

One practical detail that matters in neonatal care: the cutoff values for IL-6 are not the same at every age. Research in neonates found that an appropriate cutoff on the first day of life was 80 pg/mL, dropping to 40 pg/mL during days two through seven, and to 30 pg/mL after the first week. Using those age-adjusted thresholds, the test achieved about 75% sensitivity, 81% specificity, and a negative predictive value of 98%, meaning a low IL-6 result was very good at ruling out infection.⁸ That high negative predictive value is clinically valuable: it gives clinicians confidence to withhold or discontinue antibiotics when the IL-6 is low, helping avoid unnecessary treatment in vulnerable infants.

What Counts as a Normal IL-6 Level

In healthy adults, IL-6 levels in the blood are low, often below 7 pg/mL on most assay platforms, though the exact upper limit of normal varies by laboratory and method. A meta-analysis that pooled data from a large number of healthy donors established reference values intended to help clinicians make quick decisions, particularly in acute settings.⁹

Pregnancy shifts the reference range upward. In healthy pregnant women, normal IL-6 levels are below about 4.2 pg/mL overall, with first-trimester values slightly lower (below about 3.5 pg/mL) and second- and third-trimester values slightly higher (below about 4.4 pg/mL).¹⁰ These pregnancy-specific ranges are important because elevated IL-6 during pregnancy has been linked to preterm labor and preeclampsia; using a non-pregnant reference range could miss a meaningful elevation.

One source of confusion: “normal” is not absolute. Age, body mass, time of day, recent physical activity, and even the specific analyzer used in the lab all affect where a given person’s IL-6 sits. A mildly elevated reading in someone who just ran a marathon means something completely different from the same number in a sedentary patient with a fever. Context always matters more than the number alone.

Things That Raise IL-6 Without Infection

One of the biggest pitfalls in interpreting an IL-6 test is assuming that elevation equals infection. Plenty of non-infectious triggers cause IL-6 to spike, sometimes dramatically.

Exercise is the most striking example. Working muscles release IL-6 directly into the bloodstream, and the amount depends on how hard and how long you exercise, as well as how depleted your muscle glycogen stores are.¹¹ After a marathon, IL-6 levels can rise as much as 100-fold above baseline.¹² This exercise-driven IL-6 is not a sign of something going wrong. It functions as an energy sensor, telling the liver and fat tissue to release glucose and fatty acids to fuel the working muscles.¹³ But if blood is drawn shortly after intense exercise, the result can look alarming to someone unfamiliar with this physiology.

Obesity is another common confounder. Fat tissue, especially abdominal fat, is a steady-state producer of IL-6. People with overweight or obesity tend to have higher circulating IL-6, reflecting a kind of low-grade chronic inflammation that persists day in and day out.¹⁴ This chronically elevated baseline can muddy the interpretation of an IL-6 test ordered for an acute question like “does this patient have sepsis?” A level of 50 pg/mL in a lean person is more alarming than the same number in someone with a body mass index of 40, whose resting IL-6 may already sit in the teens or twenties.

Surgery also causes a predictable IL-6 surge. After non-emergent cardiac surgery, IL-6 rises sharply within the first 24 hours and typically plateaus within a week.¹⁵ This is a normal part of the healing response, but it means an IL-6 test drawn on the first postoperative day will almost always be elevated regardless of whether an infection is developing.

How the Sample Is Handled Affects the Result

IL-6 testing is more sensitive to sample handling than many routine blood tests, and clinicians and patients alike benefit from understanding why results can vary between labs or even between draws.

The type of blood tube matters. Plasma collected in EDTA tubes tends to give stable IL-6 readings over time, even if the sample sits at room temperature for a few hours before processing. Serum, on the other hand, can show a creeping rise in IL-6 the longer the sample sits unseparated, especially at higher temperatures. The effect disappears if the serum is centrifuged and separated from the blood cells promptly after collection.¹⁶ The practical takeaway: if your lab uses serum tubes for IL-6, a delayed spin can produce a falsely high reading.

Once separated, IL-6 is reasonably robust. Studies have found that IL-6 concentrations in serum remain stable at temperatures up to 30°C for extended periods, and repeated freeze-thaw cycles do not significantly alter the measurement.¹⁷ A short delay of a few hours between blood draw and processing also does not meaningfully change results, regardless of the anticoagulant used.¹⁸ The vulnerability, in other words, is narrowly in that window between draw and centrifugation when cells are still in contact with the serum.

Another source of variability is the testing platform itself. Different analyzer technologies can give different absolute numbers for the same sample. A study comparing ELISA and electrochemiluminescence (ECLIA) methods found that while the two correlated well, they did not agree on exact values, with a bias of about 25 pg/mL between them.¹⁹ This means you cannot directly compare an IL-6 result from one hospital with a result from another unless both use the same assay. For serial monitoring, it is important to have blood drawn and tested on the same platform each time.

IL-6 Monitoring During Anti-IL-6 Therapy

If your doctor prescribes tocilizumab, an antibody that blocks the IL-6 receptor, you might be surprised to learn that IL-6 levels in the blood actually go up during treatment, sometimes markedly. This seems paradoxical, but it makes sense once you understand the mechanism. Tocilizumab blocks the receptor that normally soaks up free IL-6, so the cytokine accumulates in the blood because it has nowhere to bind. At the same time, IL-6 signaling is effectively shut off because the drug is occupying all the receptor sites.²⁰

This detail has a practical consequence for monitoring. The elevated IL-6 during tocilizumab treatment actually reflects endogenous IL-6 production more accurately than pre-treatment levels do, because none of it is being consumed by receptor binding. In rheumatoid arthritis, research has found that patients who respond well to tocilizumab show a statistically significant rise in serum IL-6, while non-responders do not.²¹ In other words, a rising IL-6 on tocilizumab is not a sign that the drug is failing; it is a sign the drug is working. This is one of those areas where not understanding the biology behind the test number could easily lead a patient to unnecessary worry.

IL-6 in CAR T-Cell Therapy

Cytokine release syndrome is one of the most feared side effects of CAR T-cell therapy, a cancer treatment in which a patient’s own immune cells are reprogrammed to attack tumor cells. The reprogrammed cells can trigger a massive immune cascade, and IL-6 is a central driver of that storm.

Real-time IL-6 monitoring is becoming a standard part of CAR T-cell management. Research has found that the rate of IL-6 rise, measured as a log-slope over time, predicts CRS with high accuracy. In one study, a daily IL-6 increase of roughly 90% per day yielded 89% sensitivity and 92% specificity for predicting CRS, with an overall area under the curve of 0.88.²² The clinical value here is lead time: by tracking the velocity of IL-6 rise, clinicians can intervene with tocilizumab or steroids before the patient spirals into hemodynamic collapse.

IL-6 in Autoimmune Disease Monitoring

Beyond sepsis and acute-care scenarios, IL-6 testing has a role in chronic inflammatory and autoimmune conditions. Giant cell arteritis, a form of blood vessel inflammation that can threaten vision if untreated, is one example. IL-6 has been found to be more sensitive than the erythrocyte sedimentation rate (ESR), a traditional marker, for tracking disease activity in both untreated and treated patients.²³ This is clinically meaningful because ESR can be slow to reflect changes in disease activity and can remain elevated for reasons unrelated to the arteritis itself.

In joint infections after hip or knee replacement, IL-6 testing extends beyond blood. Synovial fluid drawn directly from the joint tends to be more sensitive than serum IL-6 for detecting periprosthetic joint infection, though serum IL-6 still performs well enough that researchers have recommended including it as a standard part of the workup when prosthetic failure is suspected.²⁴

How the Assay Has Changed Over the Years

The earliest IL-6 assays relied on bioassays, in which a cell line sensitive to IL-6 was exposed to a patient’s sample and the degree of cell growth served as a proxy for IL-6 concentration. Early work established that a hybridoma cell line could detect IL-6 activity at picogram levels, and the first enzyme-linked immunosorbent assays (ELISAs) could pick up concentrations as low as 50 pg/mL.²⁵ Those first-generation ELISAs required manual pipetting, incubation steps, and hours of turnaround time.

Modern automated immunoassays have pushed sensitivity far lower and speed far higher. Fully automated electrochemiluminescence platforms can return an IL-6 result in under 20 minutes, which matters enormously in a sepsis workup or CRS monitoring. A newer prototype immunoassay demonstrated tenfold greater sensitivity than the widely used Elecsys IL-6 assay, with no cross-reactivity to other cytokines.²⁶ The trend is toward faster, more sensitive, and more standardized platforms, though the lack of universal agreement on absolute values between different analyzers remains an ongoing headache for clinicians comparing results across institutions.